These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24011886)

  • 21. No mental health without physical health.
    Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
    Lancet; 2011 Feb; 377(9766):611. PubMed ID: 21334517
    [No Abstract]   [Full Text] [Related]  

  • 22. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?
    Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM
    Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.
    Faulkner G; Cohn TA
    Can J Psychiatry; 2006 Jul; 51(8):502-11. PubMed ID: 16933587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
    Kim SH; Ivanova O; Abbasi FA; Lamendola CA; Reaven GM; Glick ID
    J Clin Psychopharmacol; 2007 Aug; 27(4):365-8. PubMed ID: 17632220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Atypical antipsychotic-induced weight gain].
    Godlewska BR; Olajossy-Hilkesberger L; Marmurowska-Michałowska H; Olajossy M; Landowski J
    Psychiatr Pol; 2006; 40(5):995-1007. PubMed ID: 17217241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
    Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL
    J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weight gain in the treatment of mood disorders.
    Aronne LJ; Segal KR
    J Clin Psychiatry; 2003; 64 Suppl 8():22-9. PubMed ID: 12892538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.
    Kim E; Park DW; Choi SH; Kim JJ; Cho HS
    J Clin Psychopharmacol; 2008 Apr; 28(2):138-46. PubMed ID: 18344723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.
    Hasnain M; Vieweg WV; Hollett B
    Postgrad Med; 2012 Jul; 124(4):154-67. PubMed ID: 22913904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic syndrome and mental illness. Weight gain and other unhealthy attributes increase risk of diabetes and heart disease.
    Harv Ment Health Lett; 2011 Aug; 28(2):5. PubMed ID: 21980633
    [No Abstract]   [Full Text] [Related]  

  • 33. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weighing in: emergent diabetes mellitus and second-generation antipsychotics.
    Dufresne RL
    Ann Pharmacother; 2007 Oct; 41(10):1725-7. PubMed ID: 17785611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse effects of antipsychotic medications.
    Muench J; Hamer AM
    Am Fam Physician; 2010 Mar; 81(5):617-22. PubMed ID: 20187598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.
    McConville BJ; Sorter MT
    J Clin Psychiatry; 2004; 65 Suppl 6():20-9. PubMed ID: 15104523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms.
    Gonçalves P; Araújo JR; Martel F
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):1-16. PubMed ID: 25523882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.